Press releases // 18 September 2020
IntegraGen has announced today its financial results for the first half of 2020 with the accounts having been reviewed by the Board of Directors on 17 September 2020.
Company posts positive operating performance (EBITDA) for the second consecutive semester, supported by revenue growth (+5%) and confirms (…) »
Press releases // 16 September 2020
This press release was prepared and distributed by OncoDNA S.A. in accordance with the provisions of Articles 231-27 1 ° and 2 ° and 231-28 of the general regulations of the Autorité des marchés financiers (the “AMF”).
Press releases // 01 September 2020
IntegraGen’s Combined General Assembly for 2020 will be held on September 17, 2020 at 2 p.m. at the company’s headquarters which is located at Génopole Campus 1,Genavenir 8, Porte 840, 5 rue Henri Desbruères – 91000 Evry, France
Press releases // 09 July 2020
Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN to acquire all outstanding shares at a price of 2.20€ per share. This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of (…) »
Press releases // 09 July 2020
IntegraGen announced unaudited sales for the first half of 2020 were 4,706 k€, an increase of 13% compared to the first half of 2019 and 15% on a like-for-like basis taking into account the sale of the company’s diagnostic business at the start of 2020. The growth in sales (…) »
Press releases // 03 April 2020
+20% sales growth, positive gross operating surplus during second half of year, and close to break-even for the year
IntegraGen announced its financial results for the year ending December 31, 2019. The annual accounts were approved by the Board of Directors at a meeting held on April 2, 2020.
Operating (…) »Press releases // 26 March 2020
IntegraGen today announced Dana-Farber Cancer Institute will utilize the company’s MERCURY™ cloud-based software as part of their analysis and reporting process for sequencing data obtained from tumors of cancer patients. Dana-Farber plans to utilize MERCURY to assist in the analysis of sequencing data obtained from small and large (…) »
